Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.40    1.40 (1.08%)
Bid:
131.20
Ask:
132.60
Spread: 1.40 (1.067%)
Market Cap: £319.85m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

BTG

14 Aug 2019 17:30

RNS Number : 0959J
FTSE Russell
14 August 2019
 

 

 

 

 

 

Further to the FTSE Russell notice released on 12 August 2019 in relation to BTG (UK): Constituent Deletion, please note the FTSE 250 replacement.

 

All other details remain unchanged. Please see updated notice below:

 

BTG (UK): Constituent Deletion - UpdateChanges in FTSE UK Index Series

14 August 2019

Subject to court sanctioning the scheme of arrangement in relation to the cash acquisition of BTG (UK, constituent) by Bravo Bidco Ltd (non constituent), please see details of affected indexes and effective dates below:

 

 

 

BTG (UK, 0100159) will be deleted from the FTSE 250 Index.

 

Puretech Health (UK, BY2Z0H7) will be added to the FTSE 250 Index and removed from the FTSE SmallCap Index.

 

All changes effective from 19 August 2019.

 

Full details of index changes are available on the FTSE Russell website.

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSEZLFFKVFEBBL
Date   Source Headline
13th May 20197:00 amRNSVedanta Grows Series C Financing to $45.5 Million
7th May 20197:00 amRNSVedanta Prevails in Important EU Patent Opposition
26th Apr 20197:15 amRNSPRTC's Karuna Files IPO Registration Statement
25th Apr 20197:00 amRNSGelesis Gets $10.6M Grant to Support Manufacturing
24th Apr 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSBoehringer Ingelheim & PRTC Immuno-oncology Collab
15th Apr 20197:00 amRNSGelesis Receives FDA Clearance for First Product
11th Apr 20191:00 pmRNSAkili Makes CFO & General Counsel Appointments
11th Apr 20197:05 amRNSGelesis Presents Data on Effects of High-Fat Diet
11th Apr 20197:00 amRNSSonde Completes $16M Series A Financing Round
2nd Apr 20197:00 amRNSPRTC Presents Immuno-Oncology Programmes at AACR
1st Apr 201912:05 pmRNSKaruna expands Series B financing to $80 million
25th Mar 20196:00 pmRNSGelesis Preclinical Data on Restoring Gut Barrier
25th Mar 20196:00 pmRNSGelesis New Clinical Data on Impact of Gelesis100
21st Mar 20197:00 amRNSGelesis to Present at Endocrine Society Annual Mtg
18th Mar 20197:00 amRNSKaruna Announces $68 Million Series B Financing
15th Mar 20197:00 amRNSNotice of Results
7th Mar 20197:00 amRNSAkili & Shionogi Deal in Taiwan/Japan $20M upfront
5th Mar 20197:00 amRNSKaruna Appoints Chief Financial Officer
22nd Feb 20194:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:36 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSPRTC to Present at Two US Investor Conferences
15th Feb 20194:41 pmRNSSecond Price Monitoring Extn
15th Feb 20194:35 pmRNSPrice Monitoring Extension
14th Feb 20197:00 amRNSVor Raises $42M to Advance Leukaemia Treatment
28th Jan 20197:00 amRNSAlivio Partners to Advance Non-opioid Pain Therapy
23rd Jan 20196:08 pmRNSVedanta Immuno-oncology Candidate Published
2nd Jan 20197:00 amRNSTotal Voting Rights
28th Dec 201812:07 pmRNSSecond Price Monitoring Extn
28th Dec 201812:02 pmRNSPrice Monitoring Extension
24th Dec 20187:00 amRNSVedanta Biosciences Raise $27M Series C Financing
17th Dec 20187:00 amRNSVedanta Initiates Phase 2 Study for Lead Candidate
10th Dec 20187:00 amRNSVedanta & BMS Immuno-Oncology Collaboration
28th Nov 20187:00 amRNSVor Granted First-in-class Immuno-oncology Patent
27th Nov 20187:00 amRNSJanssen/Vedanta Phase 1 in IBD & $12M Milestone
26th Nov 20184:40 pmRNSSecond Price Monitoring Extn
26th Nov 20184:35 pmRNSPrice Monitoring Extension
22nd Nov 201812:07 pmRNSSecond Price Monitoring Extn
22nd Nov 201812:02 pmRNSPrice Monitoring Extension
16th Nov 201812:07 pmRNSSecond Price Monitoring Extn
16th Nov 201812:02 pmRNSPrice Monitoring Extension
14th Nov 201812:07 pmRNSSecond Price Monitoring Extn
14th Nov 201812:02 pmRNSPrice Monitoring Extension
13th Nov 201811:05 amRNSFull Gelesis Data Published in the Journal Obesity
7th Nov 20187:00 amRNSPRTC to Present at Jefferies 2018 in London
6th Nov 20181:00 pmRNSVedanta Presents Data on Immuno-Oncology Candidate
5th Nov 20187:00 amRNSGelesis to Present Full Data for Lead Candidate
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
17th Oct 20187:00 amRNSKaruna Adds Sage Therapeutics CEO to Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.